Table 1.
Patient Characteristics
| Sex / age | Diagnosis | Baseline/9 week PUCAI or PCDAI |
Lab changes during study* |
Concomitant Medications |
Finished study | |
|---|---|---|---|---|---|---|
| 1 | 14 yo Male | UC | 0 / 0 | None | Anti-TNF antibody therapy | Yes |
| 2 | 14 yo Female | Crohn’s disease | 0 / 0 | None | Anti-TNF antibody therapy | Yes |
| 3 | 14 yo Male | Crohn’s disease | 0 / 0 | None | Anti-TNF antibody therapy & mesalamine | Yes |
| 4 | 17 yo Male | Crohn’s disease | 0 / 0 | None | Anti-TNF antibody therapy | Yes |
| 5 | 11 yo Female | UC | 30 / 0 | None | Mesalamine therapy | Yes |
| 6 | 13 yo Female | UC | 25 | None | Mesalamine therapy | No |
| 7 | 18 yo Female | Crohn’s disease | 0 / 0 | None | Anti-TNF antibody therapy | Yes |
| 8 | 15 yo Male | Crohn’s disease | 0 / 0 | None | Mesalamine therapy | Yes |
| 9 | 12 yo Male | UC | 0 | None | Anti-TNF antibody therapy | No |
| 10 | 18 yo Male | Crohn’s disease | 5 / 0 | None | Mesalamine therapy | Yes |
| 11 | 15 yo Male | UC | 25 / 5 | None | Mesalamine therapy | Yes |
*
Labs evaluated include CBC, C-reactive protein, albumin, amylase, ALT, and creatinine.